New drug duo aims to shrink tough breast cancer before surgery
NCT ID NCT07466303
Summary
This study is testing whether a combination of two drugs, serplulimab and trastuzumab rezetecan, can effectively shrink tumors in patients with early-stage triple-negative breast cancer before they have surgery. The goal is to see if this non-chemotherapy approach can help patients achieve a complete response, potentially leading to less extensive surgery. The study will enroll about 84 female patients to evaluate the treatment's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of the Air Force Medical University
Xi'an, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.